In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Shiyi YuSchool of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Key Laboratory of the Jiangsu Higher Education Institutions for Nucleic Acid & Cell Fate Regulation, Yangzhou University, Yangzhou, Jiangsu 225009, PR China.ORCID 0000-0002-9926-852X Xue GongNanjing Women and Children's Healthcare Institute, Women's Hospital of Nanjing Medical University, 123 Tianfei Alley, Mochou Road, Nanjing, Jiangsu 210004, PR China.ORCID 0009-0006-2405-3192 Yawen YangSchool of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Key Laboratory of the Jiangsu Higher Education Institutions for Nucleic Acid & Cell Fate Regulation, Yangzhou University, Yangzhou, Jiangsu 225009, PR China.ORCID 0009-0009-3170-6907 Ying DuanSchool of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Key Laboratory of the Jiangsu Higher Education Institutions for Nucleic Acid & Cell Fate Regulation, Yangzhou University, Yangzhou, Jiangsu 225009, PR China.ORCID 0009-0002-1201-4453 Siyu ZhangSchool of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Key Laboratory of the Jiangsu Higher Education Institutions for Nucleic Acid & Cell Fate Regulation, Yangzhou University, Yangzhou, Jiangsu 225009, PR China.ORCID 0009-0006-5208-8253 Ying WangDepartment of Thyroid and Breast Surgery, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu 225009, PR China.
Zheng WangDepartment of Pathology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu 225009, PR China.
Caili BiSchool of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Key Laboratory of the Jiangsu Higher Education Institutions for Nucleic Acid & Cell Fate Regulation, Yangzhou University, Yangzhou, Jiangsu 225009, PR China.ORCID 0000-0003-1751-4377 Haibo SunSchool of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Key Laboratory of the Jiangsu Higher Education Institutions for Nucleic Acid & Cell Fate Regulation, Yangzhou University, Yangzhou, Jiangsu 225009, PR China.ORCID 0000-0002-2946-8235 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are standard therapies for estrogen receptor-positive breast cancer, but their efficacy is limited by drug resistance. While dysregulation of alternative splicing has been implicated in cancer progression, the underlying mechanisms remain unclear. Here, we uncover a splicing-mediated mechanism whereby exon 2 inclusion in
Indexed as
Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase Inhibitor p21Drug Resistance, NeoplasmExonsHistone-Lysine N-MethyltransferaseProtein Kinase InhibitorsTranscriptional ActivationAlternative SplicingCell Line, TumorCellular SenescenceFemaleGene Expression Regulation, NeoplasticHumansCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase Inhibitor p21Histone-Lysine N-MethyltransferaseProtein Kinase Inhibitors
Identifiers
PMID42853938
PMCPMC13651863
What OpenQuestion holds
Textmetadata
Read underepoch 390